489 related articles for article (PubMed ID: 19040335)
1. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
Expert Opin Pharmacother; 2008 Dec; 9(18):3145-9. PubMed ID: 19040335
[TBL] [Abstract][Full Text] [Related]
2. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
[TBL] [Abstract][Full Text] [Related]
5. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
Keck PE; Orsulak PJ; Cutler AJ; Sanchez R; Torbeyns A; Marcus RN; McQuade RD; Carson WH;
J Affect Disord; 2009 Jan; 112(1-3):36-49. PubMed ID: 18835043
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
Keck PE; Calabrese JR; McQuade RD; Carson WH; Carlson BX; Rollin LM; Marcus RN; Sanchez R;
J Clin Psychiatry; 2006 Apr; 67(4):626-37. PubMed ID: 16669728
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole alone or in combination for acute mania.
Brown R; Taylor MJ; Geddes J
Cochrane Database Syst Rev; 2013 Dec; (12):CD005000. PubMed ID: 24346956
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
Macfadden W; Adler CM; Turkoz I; Haskins JT; Turner N; Alphs L
BMC Psychiatry; 2011 Oct; 11():171. PubMed ID: 22034906
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
13. A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.
El-Mallakh RS; Marcus R; Baudelet C; McQuade R; Carson WH; Owen R
J Affect Disord; 2012 Feb; 136(3):258-66. PubMed ID: 22209190
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
[TBL] [Abstract][Full Text] [Related]
15. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
Zimbroff DL; Marcus RN; Manos G; Stock E; McQuade RD; Auby P; Oren DA
J Clin Psychopharmacol; 2007 Apr; 27(2):171-6. PubMed ID: 17414241
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
17. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients.
Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
Psychiatry Res; 2009 Jan; 165(1-2):193-6. PubMed ID: 18973955
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study.
Vieta E; T'joen C; McQuade RD; Carson WH; Marcus RN; Sanchez R; Owen R; Nameche L
Am J Psychiatry; 2008 Oct; 165(10):1316-25. PubMed ID: 18381903
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Sajatovic M; Coconcea N; Ignacio RV; Blow FC; Hays RW; Cassidy KA; Meyer WJ
J Clin Psychiatry; 2008 Jan; 69(1):41-6. PubMed ID: 18312036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
